Evidence map›Paper›PMID 35588757›Full record

ArticleThe lancet. Diabetes & endocrinology2022

Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada.

Braulio A Marfil-Garza, Sharleen Imes, Kevin Verhoeff, Joshua Hefler, Anna Lam, Khaled Dajani, Blaire Anderson, Doug O'Gorman, Tatsuya Kin, David Bigam and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in The lancet. Diabetes & endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed, 1 pooled it
36.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

109 citing papers in PubMed, 1 synthesis or guideline pooled it, 174 citations in OpenAlex.

  1. Impact of Islet Transplantation on Type 1 Diabetes-Related Complication: A Systematic Review.Transplant international : official journal of the European Society for Organ Transplantation · 2025
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Combined nonmyeloablative total lymphoid irradiation and low-dose total body irradiation enhances donor chimerism and leads to islet allograft acceptance.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026
    Article
  19. Review
  20. Article

49 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Braulio A Marfil-GarzaDepartment of Surgery, University of Alberta, Edmonton, AB, Canada; National Institute of Medical Sciences and Nutrition Salvador Zubiran, Mexico City, Mexico; CHRISTUS-LatAm Hub-Excellence and Innovation Center, Monterrey, Mexico.
Sharleen ImesClinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.
Kevin VerhoeffDepartment of Surgery, University of Alberta, Edmonton, AB, Canada.
Joshua HeflerDepartment of Surgery, University of Alberta, Edmonton, AB, Canada.
Anna LamClinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada; Division of Endocrinology and Metabolism, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Khaled DajaniClinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.
Blaire AndersonClinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.
Doug O'GormanClinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.
Tatsuya KinClinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.
David BigamDepartment of Surgery, University of Alberta, Edmonton, AB, Canada.
Peter A SeniorClinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada; Division of Endocrinology and Metabolism, Department of Medicine, University of Alberta, Edmonton, AB, Canada; Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.
A M James ShapiroDepartment of Surgery, University of Alberta, Edmonton, AB, Canada; Clinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada; Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada. Electronic address: jshapiro@ualberta.ca.
University of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIslet transplantation offers an effective treatment for selected people with type 1 diabetes and intractable hypoglycaemia. Long-term experience, however, remains limited. We report outcomes from a single-centre cohort up to 20 years after islet transplantation.

methodsThis cohort study included patients older than 18 years with type 1 diabetes undergoing allogeneic islet transplantation between March 11, 1999, and Oct 1, 2019, at the University of Alberta Hospital (Edmonton, AB, Canada). Patients who underwent islet-after-kidney transplantation and islet transplantation alone or islet transplantation before whole-pancreas transplantation (follow-up was censored at the time of whole-pancreas transplantation) were included. Patient survival, graft survival (fasting plasma C-peptide >0·1 nmol/L), insulin independence, glycaemic control, and adverse events are reported. To identify factors associated with prolonged graft survival, recipients with sustained graft survival (≥90% of patient follow-up duration) were compared with those who had non-sustained graft survival (<90% of follow-up duration). Multivariate binary logistic regression analyses were done to determine predictors of sustained graft survival.

findingsBetween March 11, 1999, and Oct 1, 2019, 255 patients underwent islet transplantation and were included in the analyses (149 [58%] were female and 218 [85%] were White). Over a median follow-up of 7·4 years (IQR 4·4-12·2), 230 (90%) patients survived. Median graft survival was 5·9 years (IQR 3·0-9·5), and graft failure occurred in 91 (36%) patients. 178 (70%) recipients had sustained graft survival, and 77 (30%) had non-sustained graft survival. At baseline, compared with patients with non-sustained graft survival, those with sustained graft survival had longer median type 1 diabetes duration (33·5 years [IQR 24·3-41·7] vs 26·2 years [17·0-35·5]; p=0·0003), median older age (49·4 years [43·5-56·1] vs 44·2 years [35·4-54·2]; p=0·0011), and lower median insulin requirements (0·53 units/kg per day [0·45-0·67] vs 0·59 units/kg per day [0·48-0·70]; p=0·032), but median HbA

interpretationWe present the largest single-centre cohort study of long-term outcomes following islet transplantation. Although some limitations with our study remain, such as the retrospective component, a relatively small sample size, and the absence of non-transplant controls, we found that the combined use of anakinra plus etanercept and the BETA-2 score were associated with improved outcomes, and therefore these factors could inform clinical practice.

fundingNone.

Indexed as

Diabetes Mellitus, Type 1Islets of Langerhans TransplantationCohort StudiesEtanerceptFemaleGraft SurvivalHumansInsulinInterleukin 1 Receptor Antagonist ProteinMaleRetrospective StudiesTreatment OutcomeEtanerceptInsulinInterleukin 1 Receptor Antagonist Protein

Identifiers

PMID35588757
OpenAlexW4280558719

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.